Application of Maastricht 2-2000 Guidelines for the Management of Helicobacter pylori among Specialists and Primary Care Physicians in Israel: Are We Missing the Malignant Potential of Helicobacter pylori?

Haim Shirin*, Shlomo Birkenfeld, Orit Shevah, Arie Levine, Julia Epstein, Mona Boaz, Yaron Niv, Yona Avni

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: The Maastricht 2-2000 guidelines on the current management of Helicobacter pylori infection were recently adopted by the Israeli Gastroenterological Association. Goal: To determine the impact of these clinical guidelines on the current knowledge, attitudes, and management of H. pylori among primary care physicians, hospital internists, and gastroenterologists in Israel. Study: Self-administered, voluntary, anonymous questionnaires were given personally to 229 physicians, 73 primary care physicians, 71 internists, and 85 gastroenterologists. The questions evaluated 4 main issues in the management of H. pylori: (1) the optimal diagnostic test, (2) indications for eradication, (3) combination and duration of triple therapy, and (4) the need for confirmation following eradication. Results: There were significant variations in the adherence of those recommendations among gastroenterologists, internists, and primary care physicians. Specifically, 94.1% of gastroenterologists and 88.9% of internists consider the urea breath test the test of choice for H. pylori diagnosis compared with 60.0% of the primary care physicians. Significant differences in the eradication indications for mucosa-associated lymphoid tissue (MALT) lymphoma, first-degree relatives of gastric cancer patients, atrophic gastritis, functional dyspepsia, and concomitant use of nonsteroidal antiinflammatory drugs were demonstrated among gastroenterologists and the other groups. Conclusions: Primary care physicians may not be aware of important indications for diagnosis and eradication of H. pylori related to the risk of gastric malignancy or concomitant use of nonsteroidal antiinflammatory drugs. Public health agencies may need to increase penetration of the Maastricht 2000 recommendations to primary care physicians.

Original languageEnglish
Pages (from-to)322-325
Number of pages4
JournalJournal of Clinical Gastroenterology
Volume38
Issue number4
DOIs
StatePublished - Apr 2004

Keywords

  • Gastric cancer
  • Helicobacter pylori
  • Maastricht 2-2000 Consensus Report

Fingerprint

Dive into the research topics of 'Application of Maastricht 2-2000 Guidelines for the Management of Helicobacter pylori among Specialists and Primary Care Physicians in Israel: Are We Missing the Malignant Potential of Helicobacter pylori?'. Together they form a unique fingerprint.

Cite this